OncoOne
OncoOne develops targeted antibody therapies to treat cancer and chronic inflammatory diseases, aiming to improve patient outcomes where current options are limited. The company engineers monoclonal and bispecific antibodies that specifically target oxMIF and uses its proprietary PreTarg-it® platform to enable targeted radioimmunotherapy. It operates as a biotech R&D company (B2B) that pursues licensing and strategic partnerships with pharmaceutical companies and research institutions, and leverages AI and data-analysis tools to optimize candidate selection and clinical development. OncoOne collaborates with external experts, maintains a US subsidiary, and is advancing its pipeline toward clinical stages to address unmet needs in oncology and chronic inflammation.
OncoOne
OncoOne develops targeted antibody therapies to treat cancer and chronic inflammatory diseases, aiming to improve patient outcomes where current options are limited. The company engineers monoclonal and bispecific antibodies that specifically target oxMIF and uses its proprietary PreTarg-it® platform to enable targeted radioimmunotherapy. It operates as a biotech R&D company (B2B) that pursues licensing and strategic partnerships with pharmaceutical companies and research institutions, and leverages AI and data-analysis tools to optimize candidate selection and clinical development. OncoOne collaborates with external experts, maintains a US subsidiary, and is advancing its pipeline toward clinical stages to address unmet needs in oncology and chronic inflammation.